Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v7-EN Version v1-EN
Language English English
Date Updated 2017-12-07 2017-11-10
Drug Identification Number 02467135 02467135
Brand name ONIVYDE ONIVYDE
Common or Proper name Irinotecan Liposome for Injection Irinotecan Liposome for Injection
Company Name IPSEN BIOPHARMACEUTICALS CANADA INC IPSEN BIOPHARMACEUTICALS CANADA INC
Ingredients IRINOTECAN HYDROCHLORIDE IRINOTECAN HYDROCHLORIDE
Strength(s) 43MG 43MG
Dosage form(s) SUSPENSION SUSPENSION
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size Vials of 43g/10ML Vials of 43g/10ML
ATC code L01XX L01XX
ATC description OTHER ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date 2017-11-07 2017-11-07
Actual start date 2017-11-08 2017-11-08
Estimated end date 2017-12-11 2017-12-11
Actual end date 2017-12-06
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments For emergency supply, please contact Baxalta customer service at +1 844 423 2090. For emergency supply, please contact Baxalta customer service at +1 844 423 2090.
Health Canada comments